Mineola, New York 11501


Purpose:

The primary purpose of this study is to determine the degree of loss of epidermal nerve fibers near a foot wound in patients with diabetic foot ulcers. The secondary purpose will be to determine whether the degree of epidermal nerve fiber loss, the clinical examination, nerve conduction studies or the molecular profile correlates with appearance of lower extremity ulcers in patients with diabetes.


Study summary:

Neuropathy is a common complication of diabetes seen in up to 43% of patients with diabetes. The relationship between neuropathy and diabetic lower extremity wounds is strong and in fact, 80% of patients with an existing diabetic foot ulcer (DFU) have neuropathy. Understanding the factors that contribute to the increased risk of wounds in patients with neuropathy is important in creating optimal strategies to reduce this risk. Traditionally, the severity of diabetic neuropathy has been evaluated using the clinical exam and nerve conduction studies. More recently, new techniques such as intra-epidermal nerve fiber density have shown promise in evaluating neuropathy especially the small nerve fiber neuropathies that might affect pain sensation and autonomic function. There are also new molecular markers that may correlate with the risk of neuropathy that may also be useful in clinically evaluating the diabetic patient with neuropathy. The primary purpose of this study is to determine the degree of loss of epidermal nerve fibers near a foot wound in patients with diabetic foot ulcers. The secondary purpose will be to determine whether the degree of epidermal nerve fiber loss, the clinical examination, nerve conduction studies or the molecular profile correlates with appearance of lower extremity ulcers in patients with diabetes.


Criteria:

Inclusion Criteria: - Age ≥ 18 years - Type 2 Diabetes defined as HgA1c ≥ 5.9% - Must be willing and able to provide written Informed Consent Exclusion Criteria: - Active osteomyelitis - Gangrene - Purulent drainage - Any experimental drugs applied topically or taken by mouth within 4 weeks of study entry - INR > 2.5


NCT ID:

NCT02347709


Primary Contact:

Principal Investigator
Mark Stecker, MD, PhD
Winthrop University Hospital

Julie DiGregorio, CCRP
Phone: (516) 663-9614
Email: jdigregorio@winthrop.org


Backup Contact:

N/A


Location Contact:

Mineola, New York 11501
United States

Julie DiGregorio, CCRP
Phone: 516-663-9614
Email: jdigregorio@winthrop.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.